Market Update (NYSE:LLY): Results of Clinical and Patient-Reported Outcomes Data for Baricitinib in Patients with Rheumatoid Arthritis to be Presented at Annual European Congress of Rheumatology (EULAR 2016)
June 07, 2016 at 07:00 AM EDT
[PR Newswire] – Lilly immunology portfolio to be featured in 16 presentations INDIANAPOLIS, June 7, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced that radiographic results from a long-term extension … Read more on this. Eli Lilly and Company (LLY) , with a current market cap of $79.02B, ended session yesterday at $74.84. Today’s price range has been between $74.51 and $74.88 per share with its 52-week range being $67.88 to $92.85. LLY shares are currently priced at 21.02x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -0.21x forward p/e ratio. And for passive income investors, the company pays shareholders $2.04 per share annually in dividends, yielding 2.72%. In a review of the consensus earnings estimate this quarter, 17 sell-side analysts are looking at $0.85 per share, which would be $0.05 worse than the year-ago quarter and a $0.02 sequential decrease. The full-year EPS estimate is $3.56 which would be a $0.13 improvement than last year’s full-year earnings. The quarterly earnings estimate is predicated on a consensus revenue forecast of $5.14 Billion. If reported, that would be a 3.21% increase over the year-ago quarter. More recently, Societe Generale Initiated LLY at Hold (Apr 6, 2016). Previously, BMO Capital Markets upgraded LLY from Market Perform to Outperform. Investors should keep in mind is that the average price target is $95.71, which is 27.89% above where the stock opened this morning. See more in (NYSE:LLY) Similar Articles: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie’s Research and Commitment to Helping People Living with Rheumatologic Diseases Highlighted at the Annual European Congress of Rheumatology (EULAR 2016) Market Update (NYSE:LLY): Lilly to Present Phase 3 Data at the American Academy of Dermatology (AAD) Annual Meeting for Ixekizumab in Psoriasis and Psoriatic Arthritis Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis